• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 413464 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414839166 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414839166 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Ariad Pharmaceuticals Shares Climbing Higher, Up 4.8%

Published on Wed, 01/02/2013 - 11:28
By Robert Cotter

Ariad Pharmaceuticals (NASDAQ:ARIA) is a company whose shares are active, trading 4.8% higher to $20.10. The S&P is currently trading 1.8% higher to 1,452 and the Dow Jones Industrial Average is trading 1.8% higher to 13,339.

Ariad Pharmaceuticals share prices have moved between a 52-week high of $25.40 and a 52-week low of $12.26 and are now trading 64% above that low price at $20.10 per share. In the last five trading sessions, the 50-day moving average (MA) has fallen 1.7% while the 200-day MA has risen 0.5%.

Ariad Pharmaceuticals has overhead space with shares priced $20.10, or 30.4% below the average consensus analyst price target of $28.88. The stock should find resistance at its 50-day moving average (MA) of $21.57, as well as support at its 200-day MA of $19.27.

ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

Zimmer Looks to Continue to Trade Above ...

Shares of Zimmer (NYSE:ZMH) traded today at $111.21, breaking its 52-week high. This n ...

Shares of Yahoo! Rise to a New 52-Week H...

Yahoo! (NASDAQ:YHOO) traded at a new 52-week high today of $46.52. So far today approx ...

Shares of Aqua America Rise to a New 52-...

Shares of Aqua America (NYSE:WTR) traded at a new 52-week high today of $26.42. This n ...

West Pharmaceutical Services: 52-Week Hi...

Shares of West Pharmaceutical Services (NYSE:WST) traded today at $51.63, breaking its ...

Recent 52-Week High Exceeded in Shares o...

Shares of WesBanco (NASDAQ:WSBC) traded at a new 52-week high today of $34.94. This ne ...

Recent 52-Week High Exceeded in Shares o...

Weingarten Realty Investors (NYSE:WRI) traded at a new 52-week high today of $36.02. S ...

Shares of WR Berkley Rise to a New 52-We...

WR Berkley (NYSE:WRB) traded today at a new 52-week high of $51.63. This new high was ...

VCA Antech: 52-Week High Recently Eclips...

Shares of VCA Antech (NASDAQ:WOOF) traded at a new 52-week high today of $45.94. So fa ...